Atrium Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 8.26 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 141.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Details
| Name | Atrium Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Founded | 2025 |
| Ceo | Kathleen Gallagher |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US04965N1046 |
| Cusip | 04965N104 |
| Cik | 0002093101 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Kathleen P. Gallagher | President, Chief Executive Officer and Director |
| Brendan Winslow | Chief Financial Officer |
| Dr. Husam Younis Ph.D., Pharm.D. | Chief Scientific Officer |
| Stephanie Kenney | Chief Corporate Affairs Officer |
| Dr. Steven George Hughes M.B.A., M.D. | Chief Medical Officer |
| Rocio Martin Hoyos | Chief Strategy Officer |
Contact
| Address | 10578 Science Center Drive, Suite 125, San Diego, California 92121, United States |
| Phone | 619 876 0700 |
| Website | https://atriumtherapeutics.com |